Pitolisant in Idiopathic Hypersomnia: Phase 3 Trial Enrollment and Early Topline Data.

Published Date: 06 Apr 2023

Using change in excessive daytime sleepiness as the primary end point, pitolisant will be evaluated in 200 patients with idiopathic hypersomnia.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

2.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

3.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

4.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

5.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot